Global Lumbosacral Radicular Pain Management Market Projected to Reach USD 1.4 Billion by 2033 with a 5% CAGR

Lumbosacral Radicular Pain Management Market

The global lumbosacral radicular pain management market is poised for significant growth, expected to achieve a market value of USD 0.9 billion in 2023 and forecasted to reach approximately USD 1.4 billion by 2033. This growth, projected at a CAGR of 5% during the forecast period from 2023 to 2033, is supported by a growing prevalence of lumbosacral radicular pain and increased demand for effective pain management solutions. Historically, the market registered a CAGR of 3.2% from 2018 to 2022, indicating a steady expansion in this therapeutic area.

Lumbosacral radicular pain, commonly referred to as sciatica, is characterized by pain that radiates along the path of the sciatic nerve, often caused by conditions such as herniated discs, spinal stenosis, or degenerative disc disease. The rising incidence of these underlying conditions is driving demand for targeted pain management therapies.

As healthcare providers seek innovative solutions to address lumbosacral radicular pain effectively, the market is expected to benefit from advancements in treatment methodologies and increased awareness of the importance of comprehensive pain management. This anticipated growth underscores the necessity for ongoing research and development in the field to improve patient outcomes and enhance quality of life for individuals suffering from this condition.

Lumbosacral radicular pain is a type of pain that originates from the lower back and radiates down the leg, typically caused by compression or irritation of the spinal nerves. The management of lumbosacral radicular pain typically involves a combination of pharmacological and non-pharmacological interventions.

The market for lumbosacral radicular pain management includes a range of products and services, including pain medications, physical therapy, spinal injections, and surgical interventions. The market is driven by factors such as the increasing prevalence of back pain, the aging population, and advancements in medical technology.

Pharmacological interventions for lumbosacral radicular pain management include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and muscle relaxants. Non-pharmacological interventions include physical therapy, chiropractic care, and acupuncture. Spinal injections, such as epidural steroid injections, can also be used to manage lumbosacral radicular pain. In cases where these interventions are ineffective, surgical interventions such as discectomy or laminectomy may be considered.

Market Competition

Key players in the market include companies such as Competition Deep Dive, Semnur Pharmaceuticals, Inc., Eliem Therapeutics, Forest Laboratories, Medtronic Spinal and Biologics, Teva Pharmaceutical, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Eli Lilly & Company, along with healthcare providers and technology companies among other global players.

• Researchers at the University of New South Wales (UNSW) Sydney and Neuroscience Research Australia (NeuRA) have developed a therapy that focuses on retraining the communication between the back and the brain. In a randomized controlled trial, the treatment was found to be effective in improving chronic back pain. The study, published in the Journal of the American Medical Association, was funded by the Australian National Health and Medical Research Council (NHMRC) and conducted at NeuRA.

The promising results of this study offer a new avenue for treating chronic back pain and improving the quality of life for those who suffer from it. The study was conducted by several universities across Australia and Europe and is a significant breakthrough in the field of pain management. In conclusion, the development of a new therapy for chronic back pain that focuses on retraining the communication between the back and the brain offers hope for millions of people worldwide. The randomized controlled trial conducted by researchers at the University of New South Wales (UNSW) Sydney and Neuroscience Research Australia (NeuRA) demonstrated the effectiveness of this treatment in improving chronic back pain.

Key Companies Profiled

Competition Deep Dive, Semnur Pharmaceuticals, Inc., Eliem Therapeutics, Forest Laboratories, Medtronic Spinal and Biologics, Teva Pharmaceutical, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Eli Lilly & Company

A Full Report Overview

Key Segments Profiled in the Lumbosacral Radicular Pain Management Industry Survey

Drug Class:

• Cyclobenzaprine
• Oxycodone
• Tramadol
• Gabapentin

Route of Administration:

• Oral
• Topical

End-User:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube